Nucleoside to treat drug-resistant HBV presented at HEP-DART

Published: 2011-12-16 06:58:00

Updated: 2011-12-16 06:58:00

Bukwang Pharmaceutical Co. announces that interim results of physician-sponsored studies of a novel antiviral compound ‘FMCA’ and its prodrugs for the treatment of chronic hepatitis B virus (HBV) was presented at the Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference being held in Hawaii between December 4 and 8 , 2011.

According to the company, the anti-HBV activity of F...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.